Sign In to Follow Application
View All Documents & Correspondence

"Novel Pharmaceutical Sustained Release Compositions And Process Of Preparation Thereof"

Abstract: Novel pharamaceutical sustained release composition comprising at least one active agent(s), or its tautomeric forms, analogues, isomers, polymorphs, sovates, or salts thereof; preferably an antiviral active agent is provided. Also provided is a process of preparation of such composition and method of using them. The sustained release compositions of the present invention are able to deliver the active agent in a desired manner for an extended period of time.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
29 June 2005
Publication Number
35/2007
Publication Type
INA
Invention Field
PHARMACEUTICALS
Status
Email
Parent Application

Applicants

PANACEA BIOTEC LIMITED
B-1 EXTN. A/27 MOHAN CO-OPERATIVE, INDUSTRIAL ESTATE, MATHURA ROAD, NEW DELHI 110044

Inventors

1. JAIN RAJESH
B-1 EXTN. A/27 MOHAN CO-OPERATIVE, INDUSTRIAL ESTATE, MATHURA ROAD, NEW DELHI 110044
2. JINDAL KOUR CHAND
B-1 EXTN. A/27 MOHAN CO-OPERATIVE, INDUSTRIAL ESTATE, MATHURA ROAD, NEW DELHI 110044
3. SINGH SUKHJEET
B-1 EXTN. A/27 MOHAN CO-OPERATIVE, INDUSTRIAL ESTATE, MATHURA ROAD, NEW DELHI 110044
4. BOLDHANEN SANJAY
B-1 EXTN. A/27 MOHAN CO-OPERATIVE, INDUSTRIAL ESTATE, MATHURA ROAD, NEW DELHI 110044

Specification

FIELD OF THE INVENTION The present invention relates to novel pharmaceutical sustained release compositions and process of preparation of such compositions preferably comprising active agent(s) having good bioavailability. Particularly this invention pertains to pharmaceutical compositions comprising antiviral active agent, process of preparation of such compositions and method of using them. BACKGROUND OF THE INVENTION The advantages of sustained release products are well known in the pharmaceutical field and include the ability to slowly release the medicament over a period of time while increasing patient compliance by reducing the number of administrations necessary to achieve the same level. Various attempts to provide dosage forms for delivery of active agent that remain in the stomach for extended periqd,s. pr time, have been described previously.

Documents

Application Documents

# Name Date
1 1680-del-2005-abstract.pdf 2011-08-21
1 1680-del-2005-form-5.pdf 2011-08-21
2 1680-del-2005-claims.pdf 2011-08-21
2 1680-del-2005-form-3.pdf 2011-08-21
3 1680-del-2005-correspondence-others.pdf 2011-08-21
3 1680-del-2005-form-2.pdf 2011-08-21
4 1680-del-2005-description (complete).pdf 2011-08-21
4 1680-del-2005-form-1.pdf 2011-08-21
5 1680-del-2005-description (provisiona).pdf 2011-08-21
6 1680-del-2005-description (complete).pdf 2011-08-21
6 1680-del-2005-form-1.pdf 2011-08-21
7 1680-del-2005-correspondence-others.pdf 2011-08-21
7 1680-del-2005-form-2.pdf 2011-08-21
8 1680-del-2005-claims.pdf 2011-08-21
8 1680-del-2005-form-3.pdf 2011-08-21
9 1680-del-2005-abstract.pdf 2011-08-21
9 1680-del-2005-form-5.pdf 2011-08-21